GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Graham Number

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Graham Number : $N/A (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-05-22), the stock price of Alseres Pharmaceuticals is $0.01. Alseres Pharmaceuticals's graham number for the quarter that ended in Jun. 2014 was $N/A. Therefore, Alseres Pharmaceuticals's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Alseres Pharmaceuticals's Graham Number or its related term are showing as below:

ALSE's Price-to-Graham-Number is not ranked *
in the Biotechnology industry.
Industry Median: 2.2
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Alseres Pharmaceuticals Graham Number Historical Data

The historical data trend for Alseres Pharmaceuticals's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals Graham Number Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alseres Pharmaceuticals's Graham Number

For the Biotechnology subindustry, Alseres Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alseres Pharmaceuticals's Price-to-Graham-Number Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's Price-to-Graham-Number falls into.



Alseres Pharmaceuticals Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Alseres Pharmaceuticals's Graham Number for the fiscal year that ended in Dec. 2013 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*-1738.825*-107.184)
=N/A

Alseres Pharmaceuticals's Graham Number for the quarter that ended in Jun. 2014 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*-1856.444*-96.26)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alseres Pharmaceuticals  (OTCPK:ALSE) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Alseres Pharmaceuticals's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Jun. 2014 )
=0.01/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Alseres Pharmaceuticals Graham Number Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines